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Human protein C 
concentrates in adult septic 
patients
ABSTRACT
Some case reports and case series suggest that protein C concentrates may improve the outcome in patients with 
congenital or acquired protein C deficiency (not only in those with sepsis induced purpura fulminans). We reviewed the 
published literature on the use of protein C concentrates in adult septic patients and found that it is limited to less than 70 
patients reported in observational studies with a 70% survival, and added our personal experience (two adult patients with 
sepsis and contraindications to recombinant activated protein C). 
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Protein C (PC) is a vitamin K-depend-
ent product of the liver, present in the 
blood similar to inactivated zymogene 
pro-enzyme and has antithrombotic, 
anti-inflammatory, and pro-fibrinolytic 
properties. During severe sepsis there 
is a reduction in PC concentration. PC 
deficiency leads to increased activation 
of the coagulation system, resulting 
in thrombin generation and, eventu-
ally, intravascular clot formation with 
thrombosis. (1) Numerous studies have 
demonstrated that decreased circulat-
ing levels of PC in septic patients are 
associated with increased morbidity 
and mortality. (2-7) The inflammatory 
and pro-coagulant host responses to 
infection are closely related. Inflamma-
tory cytokines can activate coagulation, 
inhibit fibrinolyis and stimulate multi-
ple inflammatory pathways, resulting in 
multi-organ dysfunction and death. PC 
is converted to activated PC (APC) by 
thrombin coupled to thrombomodulin 
in a selective way during the coagu-
lation cascade by inhibiting platelet 
activation and fibrin production, and is 
an important modulator of the coagula-
tion and inflammation associated with 
severe sepsis. (8)
PC is presently utilized as therapy for 
patients with congenital deficiency of 
PC, and for purpura fulminans treat-
ment. (9-11) In children and in patients 
with contraindications to the activated 
form of PC, such as those at high risk 
of bleeding, PCc administration seems 
to be a useful alternative to APC: we’ll 
review the published evidence on this 
topic. 
Even if Recombinant Human Activated 
Protein C (rhAPC, Xigris, Lilly) reduces 
all cause mortality in adult patients with 
sepsis-induced organ dysfunction with 
clinical assessment of high risk of death 
(typically APACHE II > 25 or multiple 
organ failure), (12) its use is associated 
with an increased risk of serious bleed-
ing: 2% vs 3.5% (PROWESS study), 
(13) 2.2% vs 3.9% (ADDRESS study), 
(14) 6.5% (ENHANCE), (15) with reg-
istry studies of rhAPC (16,17) reporting 
higher bleeding rates than randomized 
controlled trials, suggesting that the 
risk of bleeding in actual practice may 
be greater than reported in PROWESS 
and ADDRESS.
Contraindications for the use of rhAPC 
as per recent international guidelines 
for the management of severe sepsis 
and septic shock (12) are illustrated in 
table 1. Furthermore, the same guide-
lines indicate weak recommendations 
and low quality of evidence for the use 
of rhAPC in adult patients within 30 
days of surgery. (12) 
Some case reports suggest that PC 
concentrates (PCc, Ceprotin, Baxter) 
may improve the outcome in patients 
with congenital or acquired PC defi-
ciency such as purpura fulminans 
induced by sepsis. Most of these 
reports consider children with menin-
gococcal infections. (9-11)  Overall, 
PCc in adult septic patients has been 
reported in 8 papers (9 with the case 
reports presented in this paper) with 
overall less than 70 patients included 
in case reports or case series (18-25) 
as described in table 2. Only this paper 
and three others reported the use of 
PCc in adult patients without meningi-
tis. Other papers include double pub-
lications, (26,27) patients younger than 
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18 years of age, (10,28) or use of PCc 
in healthy volunteers. (29) 
Rintala E et al. (26) were the first (year 
1998) to report on the use of PCc in 3 
adult patients with meningitis. In 2000, 
Rintala and al. (25) increased their 
published experience describing the 
use of PC as repeatable boluses of 
100 u/kg four-a-day, associated with 
anti thrombin III (AT III) supply to reach 
normal values in 12 patients affected 
by purpura fulminans, one manifesta-
tion of disseminated or overt dissemi-
nated intravascular coagulation (DIC), 
characterized by thrombocytopenia, 
petechiae, ecchymoses associated 
with thrombosis of small vessels, result-
ing in tissue hypoperfusion that leads to 
peripheral gangrenes and acute renal 
failure. Nine of 12 patients were in sep-
tic shock and others in severe sep-
sis; median APACHE II score was 16. 
Median PC activity was 26%, median 
platelet count 27000. Etiology of infec-
tion was N. meningitidis in 4 patients, 
S. pneumoniae in 2, C. canimorsus in 
2 and 1 S. aureus, in 2 the etiology was 
unknown. Authors reported withdrawal 
of acrocyanosis, restriction of ischemic 
regions and improvement of peripheral 
temperature within the first few days 
of treatment, with concurrent improve-
ment of hemodynamic disturbance. 
Laboratory tests showed improvement 
of DIC status. Two patients required 
amputations. Twenty-eight day mortal-
ity was 33% (4 of 12) and hospital mor-
tality 42% (5 of 12). They didn’t observe 
any drug related adverse events. In a 
post hoc analysis, authors showed that 
the recovery of the platelet count was 
retarded in the non- survivor group. 
The largest experience so far has been 
reported by Baratto e al. (19) who 
described the efficacy and safety of 
PCc to restore physiological values in 
20 adult septic patients having clini-
cal contraindications to treatment with 
rhAPC such as platelets <30.000 (9 
patients), neurological pathologies 
(4 patients), high bleeding risk (3 
patients), pending major surgical inter-
ventions (2 patients), and anticoagulant 
drug therapy (2 patients). They found 
a significant increase of platelets PT, 
AT III, and a significant decrease of 
D-Dimer, aPTT, DIC score and lactate. 
They administered PCc with the aim to 
obtain 100% of the plasma PC activ-
ity using the formula: IU of PCc= (100 
– PC plasma level) x body weight (Kg). 
Continuous infusion lasted 72 hours 
and started at 3 IU/kg/h, adjusted it to 
• Active internal bleeding
• Recent (within 3 months) hemorrhagic stroke
• Recent (within 2 months) intracranial or intraspinal surgery, or severe head 
trauma
• Trauma with an increased risk of life-threatening bleeding
• Presence of an epidural catheter
• Intracranial neoplasm or mass lesion or evidence of cerebral herniation
• Known hypersensitivity to rhAPC or any component of the product
Table 1. Contraindications to the use of rhAPC as per recent international 
guidelines for the management of severe sepsis and septic shock.  (12) 
Author Year Journal N Setting Survival Bolus dose
Following 
doses
Landoni G 2008 Signa Vitae 2 Sepsis 100% 50 IU /kg 3 IU/kg/h




Sepsis after cardiac 
surgery
89% 50 IU /kg 3 IU/kg/h






Sepsis (10 surgical and 10 
medical patients)
65%
(100 – PC 
plasma level) 




Tuttolomondo A (20) 2008 Intern Emerg Med 2 Meningitis 100% Various Various
Schellongowski P (21) 2006 Vox Sang <8 Purpura fulminans 75% Various Various
Fourrier F (22) 2003 Intensive Care Med <5 Purpura fulminans 40% 100 IU/Kg 100 IU/Kg/day
Makris PE (23) 2003 J Thromb Haemost 7 DIC 71% Various Various
Vaccarella G (24) 2003 Minerva Anestesiol 1 Purpura fulminans 100% 80 IU/kg





Critical Care Med 12 Purpura fulminans 58% 100 IU/Kg
100 IU/Kg every 
6 hours
TOTAL <66 46/66=70%
N = number of patients
DIC = Disseminated Intravascular Coagulopathy
Table 2. Summary of all published papers reporting on adult patients receiving protein C concentrates (PCc).
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maintain plasma PC activity between 70 
and 120%. Baseline plasma PC activity 
was 34 ± 9.1%. The average total dose 
received by the patients (starting bolus 
plus three-day infusion) was 19.065 IU. 
Baratto et al. observed a mortality of 
35% while the predicted mortality based 
on SAPS II (55.1±13.2) was 58.9%. 
Crivellari et al. (18) described their expe-
rience with the use of PCc after cardiac 
surgery. They observed a normalization 
of coagulative parameters in a cohort of 
nine patients with sepsis induced dou-
ble organ failure, no drug related side 
effects, no hemorrhage and a 30 day 
mortality of 11%, when the predicted 
mortality at 30 days was 68% accord-
ing to the SAPS II score. They admin-
istered a fixed dose of 50 IU/kg as a 
bolus followed by a continuous infusion 
at 3 IU/kg/h that lasted 72 hours. Base-
line plasma PC activity was 33+18.2 in 
our experience. The average total dose 
received by the patients (starting bolus 
plus three-day infusion) was 15650 IU.
In 2003 Fourrier and al. (22) studied 15 
patients (adults and children) admitted 
to intensive care unit (ICU) for a very 
severe form of meningococcal purpura 
fulminans. Patients were treated con-
junctively with PC 100 IU/kg and 100 
IU/kg AT III, followed by a maintenance 
dose of 100 and 100-150 IU/kg/day 
respectively of PC and AT III. That study 
mainly indicates that the dose regimen 
of AT and PC was not sufficient to com-
pensate for the degree of consump-
tion and/or inhibition of both coagula-
tion inhibitors. Authors concluded that 
doses should be at least 150 IU/kg AT 
III and 250 IU/kg PC as a loading dose 
and 150 IU/kg and 200 IU/kg as daily 
maintenance, but taking into account 
the individual variability, repeated meas-
urements of plasma levels of PC and 
AT III are mandatory to obtain a patient 
based adjustment of the supplementa-
tion. Nine of 15 patients studied (60%) 
died.
In 2003 Makris and al. (23) treated 8 
patients with an overt DIC status with 
PC concentrates as repeated boluses 
of 80-90 IU/kg every 6 h, as adjunctive 
therapy to treat the underlining DIC 
cause. Four patients had an infection 
as the cause of DIC, 1 acute Wilson’s 
disease, 3 hematological malignan-
cies. All 8 patients had an amelioration 
of their DIC status that also affected 
mortality in 6 patients.
In 2006 Schellongowsky et al. (21) 
reported the effect of PC administration 
in 8 adult patients affected by purpura 
fulminans. Five patients received 10 
IU/kg as test dose, then a bolus of 100 
IU/kg, then  perfusion at 10 IU/kg/h; 3 
patients received the same test dose, 
then 100 IU/kg every 6 h. Patients had a 
median APACHE II score of 18, the most 
frequent diagnosis was meningitis, the 
most frequent pathogen N. meningi-
tidis. All patients had severe sepsis, 5 
had septic shock. In all patients, during 
substitution PC values increased over 
supranormal values (range 100-200%) 
and coagulopathy could be controlled 
in seven cases. One patient died early, 
one at day 14 due to the onset of sepsis 
caused by invasive candidiasis. Two 
patients required amputation of one or 
more toes, one required skin necrosec-
tomy. No adverse drug related events 
were observed. 
In 2007 Tuttolomondo et al. (20) 
described the use of PC in 2 patients. 
The first patient was a 78 year old man 
with pneumonia, not in septic shock 
but with a progressive worsening of 
clotting time and a severe risk of death 
(APACHE II score 33). Authors began 
early goal directed sepsis therapy and 
PC as a repeated bolus of 25-37.5 IU/kg 
with amelioration of clotting time. The 
patient survived and was discharged 
in good condition. The second patient 
was an 81 year old woman affected by 
a urogenital infection causing severe 
sepsis but not septic shock, at high risk 
of death (APACHE II score 31). Authors 
administered 15.3 IU/kg of PC, reported 
improvement of diuresis, conscious-
ness and clotting time but the woman 
died of abrupt cardiac arrest.
Vaccarella et al. (24) reported the use of 
PCc in an 18 y.o. patient who survived 
septic shock and purpura fulminans.
The only randomized experience on 
PCc ever published is a dose finding 
study in a pediatric population that was 
not powered to show an effect on mor-
tality rate but did show a positive effect 
on sepsis induced coagulation distur-
bances. (11)
We hereby describe two case reports 
of adult patients who received PCc 
because they were at too high a risk of 
bleeding to receive rhAPC. Two male 
patients (69 year old patient A and 65 
year old patient B) were admitted to 
the ICU of a teaching hospital because 
of septic shock (E. coli and Entero-
coccus Faecium) following urological 
surgery and chemotherapy with piastri-
nopenia. In spite of aggressive medical 
therapy, based on the 2008 updated 
guidelines for the management of sep-
sis (1) and including norepinephrine 
after aggressive fluid resuscitation and 
renal replacement therapy, the patients 
developed progressive worsening of 
tissue perfusion with multiple organ 
failure and life threatening conditions. 
They received a PCc 6000 IU bolus fol-
lowed by a continuous infusion of 200 
IU/h for three days. PC values rose from 
less than 30 to more than 70% in both 
patients during the infusion. General 
conditions improved in both patients, 
they were discharged from the ICU with 
normal renal function and were alive at 
the 30 day follow up.
Conclusions
The published literature on the use of 
protein C concentrates in adult septic 
patients is encouraging (normalization 
of coagulative parameters, no bleeding 
complications and low 30 day mortality) 
even if limited to less than 70 patients, 
including those presented in this paper. 
While rhAPC evidenced an increased 
risk of bleeding complications in rand-
omized controlled trials versus placebo, 
and registry studies report even higher 
bleeding rates than those present in 
the randomized controlled trials, (16-
17) no bleeding complication has ever 
been reported following infusion of PCc 
in adults or children. Nonetheless, in 
order to recommend the use of PCc in 
the management of severe sepsis and 
septic shock it would be necessary to 
confirm these encouraging findings 
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